Watching bioAffinity Technologies, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planbioAffinity Technologies, Inc.
bioaffinitytech.comAI Executive Summary
AI-powered analysis of 10-Q filing content
bioAffinity Technologies continues to operate as a pre-profitability diagnostics/therapeutics company reliant on external financing, generating $2.9 million in revenue for H1 2026 (up from $6.2 million for full-year 2025, implying a slower pace), while its CyPath Lung test remains commercialized only as a lab-developed test (LDT) without FDA clearance. The company explicitly warns that if financing and revenue are insufficient to meet capital needs, it may be forced to cease operations, underscoring persistent going-concern-type risk. No material legal proceedings or changes to internal controls were reported, and disclosure controls were deemed effective.
Red Flags Detected (5)
Explicit disclosure that insufficient capital could force cessation of operations
Company remains dependent on additional financing beyond limited operating revenue
CyPath Lung remains an LDT without FDA clearance, limiting broader commercial reach and reimbursement potential
2 more red flags detected
Key Takeaways
Company is revenue-generating (since 2022) but not yet profitable and remains dependent on external financing
CyPath Lung is the core commercial product, currently marketed as an LDT under CLIA/CAP oversight
3 more takeaways
Filing Overview
What This Means
Quarterly Report: Interim filing with unaudited financial data for the quarter.